First MTP Osteoarthritis

Slides:



Advertisements
Similar presentations
OSTEOARTHRITIS (OA) Rogelio A Balagat MD ASMPH.
Advertisements

HealthPartners Medical Group
Hip and Arthritis: Treatment Alternatives To Remain Active
Presentation On Non-Steroidal Anti-Inflammatory Drugs
1 DEGENERATIVE JOINT DISEASE. 2 Objectives Identify non-surgical and surgical interventions for osteoarthritis. Discuss the common complications of osteoarthritis.
Osteoarthritis Implementing NICE guidance 2008 NICE clinical guideline 59.
Initiate therapy with SSRI - ! fluoxetine 20 mg ( mg) or citalopram 20 mg ( mg) Exercise, Pt education: response expectations, followup ~ 1.
Dr Pete Rose Medical Therapy. Supplements Over-the-counter medicines Prescription medicines Injection therapy.
Management of Rheumatoid arthritis, Osteoarthritis & Gout Dr. Eoin Casey MD FRCPI, FRCP.
OSTEOARTHRITIS OSTEOARTHROSIS DEGENERATIVE JOINT DISEASE
Case Presentation 65 yr, male C/O right knee pain, stiffness Can not walk more than 10 mts Can not sleep at night Walks with frame 30/12//20121.
Analgesics for Osteoarthritis — An Update Prepared for: Agency for Healthcare Research and Quality (AHRQ)
By Amy Lovern, RN, BSN.  Osteoarthritis (OA) is one of the oldest and most common forms of arthritis.  Known as the “wear and tear” kind of arthritis.
Osteoarthritis (OA): Updates on development, treatment and possible prevention Kevin Deane, MD/PhD Associate Professor of Medicine Division of Rheumatology.
 صدق لله العلي العظيم سورة طه الايه 114 فَتَعَالَى اللَّهُ الْمَلِكُ الْحَقُّ وَلا تَعْجَلْ بِالْقُرْآنِ مِنْ قَبْلِ أَنْ يُقْضَى إِلَيْكَ وَحْيُهُ وَقُلْ
Chapter 12 Anti-inflammatory Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Nonsteroidal.
Osteoarthritis By: Tilly Paterson and Amanda Elsaesser.
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
Objectives Define arthritis List risk factors
Part III Amy L. McIntosh, MD Pediatric Orthopedic Surgeon Mayo Clinic Rochester, Minnesota.
Osteoarthritis. Mr. P 45y Plumber BL knee pains OA diagnosed on XR.
OSTEOARTHRITIS. Osteoarthritis (OA) is a common, degenerative disease, which is characterized by local degeneration of joint cartilage and new bone formation.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 18 Nonopioid Analgesics: Nonsteroidal Anti-Inflammatory Drugs.
Case #13 Ellen Marie de los Reyes March 15, 2007.
The Growing Knee OA Population
Dr. Mahboob Ur Rahman BSPT,PPDPT,EMBA Chief Physiotherapist HMC Peshawar/ Founder &Chairman Mahboob School of Physiotherapy Hayatabad.
Spa therapy for lumbar spine osteoarthritis M. Zeki Karagülle Istanbul University Istanbul Medical Faculty Department of Medical Ecology and Hydroclimatology.
Osteoarthritis.  Osteoarthritis OA is a degenerative disease of diarthrodial ( synovial ) joints, characterized by  Breakdown of articular cartilage.
DEGENERATIVE JOINT DISEASE = OSTEOARTHRITIS. DEGENERATIVE JOINT DISEASE Degenerative joint disease is chracterized by: 1. pain 2. stiffness 3. loss of.
Osteoarthritis (OA) Dr. Timothy Payne, MD. What is Osteoarthritis? Osteoarthritis is primarily a non- inflammatory degenerative disorder of moveable joints.
No MRI Needed Osteoarthritic kneeHealthy knee. Burden of Disease 39.4 million visits to physicians offices 750,000 hospitalizations OA cost $125 billion/year.
Glucosamine Chondroitin
Osteoarthritis ---About osteoarthritis cause, treatment and conclusion. ---By Yanhong, Sharmila and Jiah.
Osteoarthritis. What is osteoarthritis (OA)? Degenerative joint disease Slowly evolving disease Originates in the cartilage Causes inflammation of the.
OSTEOARTHRITIS (OA) is the most common form of arthritis. It has a strong relation with ageing as its a major cause of pain and disability in older people.
What You Need to Know about JOINT HEALTH. This presentation is for educational purposes only. Please consult with your health care provider before taking.
Hot Topic Presentation Lars Halford, GP ST3 March 2010
An unpleasant sensory or emotional experience associated with actual or potential tissue damage The World Health Organization (WHO) has stated that pain.
East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast NSAIDS – Efficacy and Safety Expert speaker.
Joint Injuries Arthritis By: Alessandro Iunni, Simon Da Silva, and Dylan Mugford.
Primary Care Management The Hip Andrew Pearse Consultant Trauma and Orthopaedics Worcestershire Acute Hospitals NHS Trust.
FUNCTIONAL OUTCOME OF TOTAL KNEE REPLACEMENT USING INDUS PROSTHESIS Dr. L.k.lelei Specialist orthopedic surgeon Moi university, school of medicine.
Osteoarthritis Name : Abdulaziz Bader ID:
Chronic Pain Management in OA knee
Hip & Knee OA: 5 Pearls to Delay the Dreaded Total Joint Replacement
NONSTEROIDAL ANTIINFLAMATORY DRUGS(NSAIDS)
Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.
Loyola-Provident-Cook County Family Medicine Residency
Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.
Arthritis All answers are TRUE for the T/F questions.
OSTEOARTHRITIS DEGENERATIVE JOINT DISEASE
Dr.Fakhir Yousif.
Treatment Goal of treatment reduce inflammation and pain
Aging Alice Group 9.
Dr (Prof) RAJU VAISHYA (MBBS, MS, MCh, FRCS)
OA.
54 Osteoarthritis.
A Recommendation from Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from ACOP and APS By Rhys Dela Cruz, Angela Hickey,
Non-Surgical Management of Osteoarthritis
بسم الله الرحمن الرحیم.
Optimizing Therapy for Osteoarthritis
1- Mention the most important anaerobic bacteria? 2- Describe the most places for anaerobic bacteria ? 2- Mention the anaerobic infections with causative.
ACUTE PAIN MANAGEMENT FOR EMS
Terms and Definitions Analgesics:
pain management Lecture headlines :
Lecture 8 Rheumatologic Disorders Osteoarthritis
Kelly Schatzlein PA-S and Keely Tietjen PA-S
Brian L. Lohrbach, MD Board-Certified Orthopedic Surgeon
Medications for Osteoarthritis:
Non opioids pain management
Presentation transcript:

First MTP Osteoarthritis Hallux valgus with bunion

OA is a Problem with the Cartilage!

Osteoarthritis: Risk Factors Secondary Osteoarthritis: The degeneration is secondary to an injury to the cartilage Primary Osteoarthritis: No obvious cartilage injury Erosive (hand) OA: runs in families, autosomal dominant but more penetration in women Often starts 5-10 years pre to post menopause, adds more joints (DIPs, PIPs), can mimic psoriatic arthritis, burns out with bony changes

Risks for OA Advanced Age Female Genetics Obesity Occupation (overuse) Trauma

Osteoarthritis: Laboratory All laboratory investigations should be normal in osteoarthritis Labs and Xrays are not necessary to make the diagnosis

Osteoarthritis: Management Non-Pharmacologic Exercises Strengthening Splinting Pharmacologic Oral Medications Surgery Topical Medications Injectable Medications Alternative/Complimentary Choices

Goals of Treatment Pain Reduction Improved Function Changes the Disease Outcome Low Cost Low Side Effects

Physical & Occupational Therapy Proper Footwear Strength Training Assistive Devices Physical & Occupational Therapy Exercise & Weight Loss Education

Topical Medications Capsaicin Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Pennsaid, Diclofenac

Topical NSAIDs Messy Benefits Little systemic absorption Limited Use for Osteoarthritis Small effects in clinical trials Apply 4 times per day Expensive Messy Benefits Little systemic absorption

Intra-Articular Corticosteroids Pros Cheap Relatively Safe: 1 in 15-20,000 risk of infection Safe to do 4 injections in a single joint per year Cons Short term benefit at 4 to 8 weeks but negative at 12 and 24 weeks Predictors of response are unclear

Viscosupplementation Joints typically contain a small amount of lubricating fluid called synovial fluid. Hyaluronic acid is a component of this synovial fluid Synovial fluid Hyaluronic acid is decreased in patients with osteoarthritis Viscosupplements are synthetically or biologically derived Hyaluronic Acid

Viscosupplementation Given by a series of 1 to 3 injections once a week depending on the product Only approved for osteoarthritis of the knee The effects are variable lasting months in some people and not working at all in others

Viscosupplementation Pros If it works, may have a significant benefit Cons Expensive ~ $300 per course The effects are variable lasting months in some people and not working at all in others Post-injection pain, swelling Not very good clinical trial data

Oral Medications Simple Analgesics Non-Steroidal Anti-Inflammatory Medications (NSAIDs) Narcotic Analgesics and non-narcotic (tramadol) Complimentary Therapy (Glucosamine)

Acetaminophen Acetaminophen (Tylenol ) Useful in mild to moderate osteoarthritis Pros Cheap Safe Proven Benefit Cons Small effect Often need 3g/day

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Traditional NSAIDs COX-2 Selective NSAIDs (COXIBs)

Prostaglandin Synthesis Cell Membrane Phospholipids Arachidonic Acid NSAIDs NSAIDs COX-1 COX-2 Prostaglandins Prostaglandins COX-1 Continuously Expressed GI Tract Platelets Endothelium Kidney COX-2 Upregulated Synovial Lining Macrophages Chondrocytes Endothelium Macula Densa

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Traditional NSAIDs Block the Actions of COX-1 and COX-2 Available Over the Counter (Ibuprofen) Several (Ibuprofen, Diclofenac, Naproxen, etc) COX-2 Selective NSAIDs (COXIBs) Only Block the Action of COX-2 Only 1 available – Celecoxib (Celebrex)

NSAIDs & COXIBs: What Works NSAIDs consistently outperform acetaminophen in OA treatment

NSAIDs & COXIBs: What to look out for GI Risk – gastric and duodenal ulcer Renal Risk – raise creatinine and HTN Cardiovascular Risk - ?increased MIs Hepatoxicity Edema Allergic reactions

Clinical Risk Factors for NSAID Gastropathy History of Ulcer Related Complications 13.5% Previous ulcer, bleeding Multiple NSAIDs 9.0 % High-dose NSAIDs 7.0 % Concomitant Anticoagulation 6.4% Age > 69 5.6% Age > 59 3.1% Concomitant Steroids 2.2% History of CV disease 1.8%

More Patients are Without Appropriate Gastroprotection Patients >65 years not receiving gastroprotective approaches with their NSAIDs (%) Year 100 80 60 40 20 Singh G, et al. Gastroenterology 2006; 130(Suppl. 2): A-82 (Abstract 564).

NSAIDs & COXIBS: Cardiovascular All NSAIDs may increase the risk of MI (possibly) and some more than others Use the lowest possible dose for the shortest duration of time

Narcotics Benefits Side Effects Risk for Falls and other Accidents Codeine does have some evidence for efficacy, however, it also has a high incidence of side-effects. Oxycodone, morphine, and hydromorphone may be better choices Side Effects Increaed in the elderly Sedation, confusion, constipation Risk for Falls and other Accidents

Addiction It is EXCEEDINGLY rare for patients with OA to show addictive behaviour. In fact, a study of over 800 patients with OA treated with opioids for 3 years found only 4 (0.02%) to have addictions. (Ytterberg S, Mahowald M, Woods S. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 1998;41:1603-12.) OA patients stop opioids after surgery. (Visuri T, Koskenvuo M, Honkanen R. The influence of total hip replacement on hip pain and the use of analgesics. Pain 1985;23:19-26.)

Glucosamine: The Theory Glucosamine is a component of cartilage Glucosamine is reduced in osteoarthritic cartilage Replacing glucosamine may have beneficial effects

Glucosamine: The Evidence You are a believer or not Both positive and negative trials Withdrawal trial and NIH trial were both essentially negative DONA (RottaPharm) Only brand of glucosamine to show positive benefit in trials All trials sponsored by pharmaceutical company

Glucosamine: Practicality Dose: 500 mg three times daily If no effect after 3 months stop ? Take with chondroitin Seems very safe

Surgery for Osteoarthritis

Surgery: Who is appropriate Most people with arthritis, including older individuals, should be referred for surgical treatment when other treatment is ineffective and function is impaired. Surgery should not be used as a last resort There is no “magic age” for surgery

Surgery: Why Consider Consider surgery before: Advanced muscle weakness Joint deformities Significant loss of function with further deconditioning

Treatment Conclusions Non-Pharmacologic Therapy Education Physical Therapy Assessment Strengthening Range of Motion Joint Protection & Energy Conservation Weight Loss & Nutrition Cardiovascular Exercise Shoes & Insoles Assistive Devices

Treatment Conclusions NSAIDs Work very well in select patients Try a few NSAIDs before find the right one for you. 3 week trials of at least 3 different NSAIDs. Injectable Corticosteroids Work well in some patients Viscosupplementation Can work well in some patients (milder disease) Opioids Can provide considerable benefit

Treatment Conclusions Lack of Scientific Evidence for Acupuncture Magnet Therapy

OA Guidelines Other Exercise Brace, Taping Weight Loss Joint replacement Medications Acetaminophen NSAIDs/Coxibs Topical agents Injectable agents

Questions